News | Prostate Cancer | February 03, 2017

New Treatment Regimen Extends Life for Some Men With Recurrent Prostate Cancer

Cedars-Sinai study finds adding hormonal therapy to radiation therapy significantly improves long-term death and metastasis rates

recurrent prostate cancer, hormone therapy, radiation therapy, Cedars-Sinai study, New England Journal of Medicine

February 3, 2017 — Adding hormonal therapy to radiation treatment can significantly improve the average long-term survival of men with prostate cancer who have had their prostate gland removed, according to a new Cedars-Sinai study published in the Feb. 2 issue of the New England Journal of Medicine. The regimen also can reduce the frequency of spread of the cancer, the study found.

Prostate cancer is the second most common cancer in U.S. men. An estimated 161,300 new cases will be diagnosed and nearly 27,000 deaths are expected in 2017, according to the American Cancer Society.

“Our study indicates that hormonal treatments should be incorporated into the management of men who need radiation therapy after surgery for prostate cancer,” said Howard Sandler, M.D., chair of the Department of Radiation Oncology in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai and senior author of the multicenter study.

More than 30 percent of prostate cancer patients face the return of disease one to four years after removal of the prostate gland, Sandler said.

When a patient experiences a recurrence, physicians typically prescribe radiation therapy. “Our results show that adding hormone therapy could add years to patients’ lives,” Sandler said.

The study, which included researchers at 17 medical institutions, tracked 761 prostate cancer patients in the U.S. and Canada during a 12-year period after they had participated in a randomized clinical trial of the combined treatment, from 1998 to 2003.

The study’s findings include:

  • After 12 years, the incidence of deaths from prostate cancer was 5.4 percent for patients who underwent radiation therapy plus hormone treatment, compared with 13.4 percent for those who had only radiation therapy;
  • The incidence of prostate cancer metastasis was 14.5 percent for patients who received both treatments, compared with 23 percent for those who had only radiation therapy; and
  • Side effects were low and similar in both groups of patients.
     

The hormonal treatment used in the study was designed to suppress male hormones, known as androgens, which can stimulate growth of prostate cancer cells. Randomized study participants took the drug daily for two years. The specific drug they received, bicalutamide, has since been supplanted by another drug, GnRH agonists, in clinical practice, Sandler said. But because both drugs suppress hormone production, he said the study presents "proof of principle" that combining hormonal therapy with radiation treatment significantly reduces the rate of metastases and death in the patient group studied.

“This important research addressed a significant question in the care of patients with prostate cancer, showing the continued advancement in extending a good quality of life to those patients,” said Steven Piantadosi, M.D., Ph.D., director of the Samuel Oschin Comprehensive Cancer Institute. “Dr. Sandler’s leadership demonstrates how Cedars-Sinai is contributing significantly to improving the outcomes of patients with cancer.”

Sandler said that future studies will explore whether all or only some prostate cancer patients need hormone therapy, the duration of treatment and the role of more powerful hormone therapies.

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health, under award numbers U10CA21661, U10CA180868, U10CA180822 and UG1CA189867, and by a grant from AstraZeneca.

For more information: www.nejm.org

Related Content

During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging, and repeat biopsies.

Getty Images

News | Prostate Cancer | November 18, 2020
November 18, 2020 — ...
Penn study supports the use of more testicular shielding for men and children during diagnostics

Getty Images

News | Radiology Imaging | November 16, 2020
November 16, 2020 — Early and repeated exposures to diagnostic imaging, such as X-rays and...
Minimizing delays to treatment could improve cancer survival rates, say researchers

Getty Images

News | Radiation Oncology | November 10, 2020
November 10, 2020 — People whose treatment for cancer is delayed by even one month have in many cases a 6 to 13% high
In this retrospective cohort study of men with low-risk prostate cancer followed up for a median of 7.6 years, African American men, compared with non-Hispanic White men, had a statistically significant increased 10-year cumulative incidence of disease progression and definitive treatment, but not metastasis or prostate cancer–specific mortality

Getty Images

News | Prostate Cancer | November 04, 2020
November 4, 2020 — Previous studies have shown that African American men are 2.4 times as likely to die from...
Metastasis-free survival is a strong surrogate endpoint for overall survival over biochemical failure for men receiving salvage radiotherapy for recurrent prostate cancer

Getty Images

News | Prostate Cancer | November 02, 2020
November 2, 2020 — An analysis of the...
Watch-and-Wait Compared to Operation for Patients with Complete Response to Neoadjuvant Therapy for Rectal Cancer. Image courtesy of the American College of Surgeons

Watch-and-Wait Compared to Operation for Patients with Complete Response to Neoadjuvant Therapy for Rectal Cancer. Image courtesy of the American College of Surgeons

News | Radiation Therapy | November 02, 2020
November 2, 2020 — A nonsurgical treatment option for...